A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer

Background This multicentre, open-label, Phase Ib/II trial evaluated the insulin-like growth factor (IGF) 1/2 neutralising antibody xentuzumab plus enzalutamide in metastatic castrate-resistant prostate cancer (mCRPC). Methods The trial included Phase Ib escalation and expansion parts and a randomis...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	British journal of cancer Ročník 129; číslo 6; s. 965 - 973
Hlavní autoři:	Macaulay, Valentine M., Lord, Simon, Hussain, Syed, Maroto, José Pablo, Jones, Robert Hugh, Climent, Miguel Ángel, Cook, Natalie, Lin, Chia-Chi, Wang, Shian-Shiang, Bianchini, Diletta, Bailey, Mark, Schlieker, Laura, Bogenrieder, Thomas, de Bono, Johann
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	London Nature Publishing Group UK 05.10.2023 Nature Publishing Group
Témata:	631/154 631/67/589/466 692/4028/67/589/466 Antibodies, Neutralizing Antineoplastic Combined Chemotherapy Protocols - adverse effects Biomedical and Life Sciences Biomedicine Cancer Research Castration Drug Resistance Epidemiology Humans Insulin-like growth factor I Insulin-like growth factors Male Metastases Metastasis Molecular Medicine mRNA Nitriles - therapeutic use Oncology Prostate cancer Prostate-specific antigen Prostatic Neoplasms, Castration-Resistant - pathology PTEN protein Treatment Outcome
ISSN:	0007-0920, 1532-1827, 1532-1827
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!